Frank Striebel

Frank Striebel is a seasoned professional in clinical pharmacology, currently serving as Senior Global Clinical Pharmacology Manager at Sandoz since November 2020. Prior experience includes roles at MorphoSys AG, where Frank held positions as Associate Director Clinical Pharmacology & Bioanalytics, Senior Scientist, and Scientist, focusing on pivotal projects such as the development of tafasitamab, which led to successful regulatory submissions. Earlier research experience includes postdoctoral positions at the Max Planck Institute for Biochemistry and ETH Zurich. Frank Striebel holds a PhD from ETH Zurich and has degrees in biochemistry from the Technical University of Munich at both the master's and bachelor's levels.